News/ News/ Oncology/ Top stories Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China Richard Staines cancer immunotherapy, CStone, Pfizer 0 Comment Pfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration Share X Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China https://pharmaphorum.com/news/pfizer-picks-up-rights-to-cstones-cancer-immunotherapy-sugemalimab-in-china/
